The possibility that there may be immunological markers for Alzheimer' s disease would be of clinical and theoretical importance. To date the association between Alzheimer's disease and certain histocompatibility antigens has been questioned3 and the finding of abnormally raised levels of immunoglobulins in cognitively impaired elderly4 has not been replicated.5 However, Pouplard et al6 using an indirect immunofluorescence test on cryostat sections of human post mortem pituitary (2-3 hours after death), recently reported that 26 of 27 cases of Alzheimer's disease, and 10 of all 11 cases of Down's syndrome with dementia (where the neuropathological changes parallel those of Alzheimer's), have been sera positive for prolactin cell autoantibodies. A control group of normal 80 year olds and patients with Parkinson's disease had much lower rates of positive reactions (three of 21 and two of 40 respectively). Three out of 10 patients with multi-infarct dementia had prolactin cell autoantibodies. These antibodies were first described in patients with autoimmune polyendocrine disease7 and rarely occur in the general population.'9
The unexpected findings of Pouplard have attracted world-wide interest and we know of several groups who are attempting to replicate these results. In view of its
